Definition of Vaccine:
| Name of Vaccine | History | Year | Available in Market |
| Poliovirus Vaccine (IPV) Oral poliovirus vaccines (OPV) | Hilary Koprowski | 1950 | 1. Primopol Oral Poliovirus Vaccine (Panacea Biotec Ltd) |
| Cholera vaccine (OCVs) | Louis Pasteur | 1897 | 1. Shanchol (Sanofi India Ltd) |
| Anthrax vaccine | Louis Pasteur | 1904 | 1. Priorix Vaccine (GSK) |
| The bacille Calmette-Guérin (BCG) vaccine for Tuberculosis | Albert Calmette and Camille Guérin | 1921 | 1. SII-Onco-BCG Injection (Serum Institute of India Ltd) 2. Onco Bcg (Cipla Ltd) 3. Oncovac (Zydus Cadila) |
| Pneumonia vaccine (PCV or PPSV) | Sir Almroth Wright | 1911 | 1. Prevnar20 (Pfizer) 2. Vaxneuvance (Merck) 3.PNEUMOSIL® (Serum Institute of India Ltd) 4.Pneumovax 23 Vaccine (MSD) 5.Prevenar 13 Vaccine (Pfizer) 6.Synflorix Vaccine (Glaxo SmithKline Pharmaceuticals Ltd) 7. Pulmovax 23 Injection (Lupin Ltd) |
| Rabies virus | Louis Pasteur and Émile Roux | 1985 | 1. RabAvert & Rabipur (Glaxo SmithKline Pharmaceuticals Ltd) 2. Xprab (Sun Pharmaceutical Industries Ltd) 3. Rabies (Rabivax) (Serum Institute of India Ltd) 4. Indirab (Bharat Biotech) 5. Verorab (Zuventus Healthcare Ltd) 6.Worab (Wockhardt Ltd) |
| Pertussis (Whooping Cough) | Pearl Kendrick, Loney Gordon and Grace Eldering | 1930 | 1. Usually in Combine (DTP Vaccine) |
| Hepatitis A (HAV) and Hepatitis B (HBV) | Hepatitis A (HAV) : “Vaqta” developed by Maurice Hilleman and his team at Merck & Co. Hepatitis B (HBV) Maurice Hilleman and his team | 1995 (HAV) 1981 (HBV) | For HAV : A. Vaqta B. Havrix for HAV (GSK) (1995) C. Avaxim: made by Sanofi Pasteur. For HBV: 1. Recombivax HB (Merck), 2. Engerix-B (GSK), 3. Elovac B (Human Biologicals Institute, a division of Indian Immunologicals Limited), 4. Genevac B (Serum Institute) 5. Shanvac B (Sanofi India Ltd) 6. Heplisav-B, and 7. PreHevbrio 8. Heparel (Reliance Life Sciences) 9.Revac-B (Bharat Biotech) 10. Hepaglob (Sun Pharmaceutical Industries Ltd) 11. HB Vac (Zydus Cadila) 12.Biovac B (Wockhardt Ltd) Combine Dose: 1. Infanrix Hexa Vaccine for Prevention of Diphtheria Prevention of Tetanus Prevention of Pertussis Prevention of Polio Prevention of Haemophilus influenzae Type b disease Prevention of Hepatitis B infection |
| Hepatitis C (HCV) | No Vaccine | NA | NA |
| Hepatitis A and B vaccine | GlaxoSmithKline | 2001 | 1. Twinrix (GlaxoSmithKline) |
| Hepatitis A and typhoid vaccine | GlaxoSmithKline | NA | 1. Hepatyrix (GlaxoSmithKline) 2. ViVaxim and ViATIMfrom by Sanofi Pasteur |
| Measles | John Franklin Enders, and his Team Maurice Hilleman at Merck & Co. (Improved Version of Vaccine) | 1963 1968 | 1. Measles vaccine 2. Attenuvax |
| Rotavirus | RotaShield, (Wyeth Pharmaceuticals) | 1998 | 1. Rotarix (GlaxoSmithKline) 2. RotaTeq (Merck) 3. Rotavac (Bharat Biotech International Limited.) 4. Rotasiil (Serum Institute of India) 5. Rotasure Oral Vaccine (Abbott) |
| Mumps | United States government targeted mumps for scientific research Maurice Hilleman of Merck & Co. (First Effective Vaccine) | 1948 1967 | Now a day MMR, MMRV or other combined vaccine are user instead of single target. 1. Mumpsvax (Merck & Co.) |
| Rubella (German Measles) | Parkman, Meyer, and the team from the NIH | 1969 | 1. Meruvax II Rubella (Serum Institute of India Ltd) 2. R-VAC Vaccine (Serum Institute of India Ltd) |
| MMR vaccine (a combination with the rubella vaccine and mumps vaccine) | Maurice Hilleman and his team. | 1971 | 1. Merck (first) |
| MMRV vaccine (a combination of MMR with the chickenpox vaccine) | Merck (Commercialization) | Around 1971 | 1. Tresivac (Serum Institute of India Ltd) 2. Priorix Vaccine (GSK) 3. M-M-R II (MSD) |
| Typhoid fever | Richard Pfeiffer and Wilhelm Kolle | 1896 | 1. Typbar TCV Vaccine (Bharat Biotech) 2. Typhibev Vaccine (Biological E Ltd) 3. Shantyph 25mcg Vaccine (Shantha Biotech) |
| Influenza viruses (A and B) | Thomas Francis Jr., MD, and Jonas Salk, MD | 1945 (US Militry) | 1. Influenza Injection (Serum Institute) 2. Agrippal S1 (Panacea Biotec Ltd) 3. Influvac (Abbott) 4. Vaxigrip (Sanofi India Ltd) |
| Varicella (Chickenpox) vaccine | Maurice Hilleman’s team at Merck (Work on it) Michiaki Takahashi was a Japanese virologist, best known for inventing the first chickenpox vaccine and having attenuated the varicella zoster virus to produce the Oka vaccine. Japan was first to use vaccine | 1984 | 1. Varilrix Vaccine (GSK) 2. Biovac V Vaccine (Wockhardt Ltd) 3. Variped (MSD Pharmaceuticals Pvt Ltd) 4. Zuvicella (Zuventus Healthcare Ltd) 5. Varivaxo (Panacea Biotec Ltd) 6.Okavax (Sanofi India Ltd) |
| Meningococcal polysaccharide vaccine | The first vaccine — meningococcal polysaccharide vaccine or MPSV4 | 1978 | NA |
| Meningococcal serogroup B vaccine | Wyeth Pharmaceuticals | 1970 2015 (Approved) | 1. Trumenba (Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.) 2.Bexsero (Novartis) |
| Meningococcal conjugate (MCV) (Quadrivalent) | Sanofi Pasteur | 2005 | 1. Menactra® (Sanofi India Ltd), 2. Menveo® (GSK), and 3. MenQuadfi (Sanofi) |
| HPV vaccine (Human papillomavirus vaccines) | Ian Frazer and Jian Zhou of University of Queensland in Australia Harald zur Hausen (who suspected HPV for Cervical Cancer) Merck & Co. (MSD) | 2006 (MSD) | 1. Gardasil (MSD Pharmaceuticals Pvt Ltd) 2. Cervarix (GlaxoSmithKline) 3. Gardasil 9 (MSD) 4. Silgard (MSD) |
| Tetanus vaccine (Tetanus Toxoid (TT)) | Emil von Behring & his German group (passive immunology) | 1890 | 1. Tetglob 500IU Injection (Bharat Biotech) |
| Diphtheria, tetanus, and whooping cough (DPT vaccine or DTP vaccine)- Triguni Vaccine | NA | 1949 | 1. Infanrix Vaccine (GSK) 2.Triple Antigen Vaccine (Serum Institute of India Ltd) 3. Boostrix Vaccine |
| Tetanus Toxoid + Diphtheria Toxoid + Pertussis Toxoid + Hepatitis B Vaccine (rDNA) | NA | NA | 1. SII Q-VAC Vaccine (Serum Institute of India Ltd) 2. Quadrovax SD Vaccine (Serum Institute of India Ltd) |
| Hexavalent vaccine (diphtheria, tetanus, pertussis, poliomyelitis, haemophilus B, and hepatitis B) | Hexavacand for Infanrix hexa by EU. | 2000 | 1. Hexaxim Vaccine (Sanofi India Ltd) 2. Easy Six (Panacea Biotec Ltd) 3.Infanrix hexa (GSK) |
| Penta Valent Vaccine (Known as Panchgunu Vaccine ) diphtheria, tetanus, pertussis, hepatitis B, and poliomyelitis. | GlaxoSmithKline | 2002 | 1.Pediarix (GSK) 2. Pentaxim Vaccine (Sanofi India) |
*Vaccine List table are reference only. Vaccine effectiveness is depended on Government clinical criteria. Please consult your doctor for further information.
| Type of Vaccine | Mode of Action | Issues | Examples |
| Inactivated vaccines | It uses the killed version of the germ that causes a disease | It doesn’t provide immunity (protection) that’s as strong as live vaccines, as a result need over a time booster dose. | Hepatitis A Flu (shot only) Polio (shot only) Rabies Covaxin (Covid 19) |
| Live-attenuated vaccines | Live vaccines use a weakened (or attenuated) form of the germ that causes a disease. It works similar to the natural infection that help prevent, they create a strong and long-lasting immune response. Just 1 or 2 doses of most live vaccines can give you a lifetime of protection against a germ and the disease it causes. | Not suitable for weaken immunity.Storage condition | Measles, mumps, rubella (MMR combined vaccine) Rotavirus Smallpox Chickenpox Yellow fever |
| Messenger RNA (mRNA) vaccines | mRNA vaccines make proteins in order to trigger an immune response. | First Used in Covid-19 | Pfizer-BioNTech or Moderna (COVID-19 mRNA vaccines) |
| Subunit, recombinant, polysaccharide, and conjugate vaccines | Subunit, recombinant, polysaccharide, and conjugate vaccines use specific pieces of the germ—like its protein, sugar, or capsid (a casing around the germ). Because these vaccines use only specific pieces of the germ, they give a very strong immune response that’s targeted to key parts of the germ. | Drawback is Patient need to take booster dose for on going protection. | Hib (Haemophilus influenzae type b) disease Hepatitis B HPV (Human papillomavirus) Whooping cough (part of the DTaP combined vaccine) Pneumococcal disease Meningococcal disease Shingles Novavax (Covid 19) |
| Toxoid vaccines | A toxin (harmful product) made by the germ that causes a disease. They create immunity to the parts of the germ that cause a disease instead of the germ itself. | Patient need to take booster dose for on going protection. | Diphtheria Tetanus |
| Viral vector vaccines | Viral vector vaccines use a modified version of a different virus as a vector to deliver protection. Several different viruses have been used as vectors, including influenza, vesicular stomatitis virus (VSV), measles virus, and adenovirus, which causes the common cold. | Adenovirus is one of the viral vectors used in some COVID-19 vaccines being studied in clinical trials. | Replicating viral vector vaccines infect cells Examples: Recombinant vesicular stomatitis virus (rVSV)- Zaire Ebola virus vaccine and The live attenuated tetravalent dengue vaccine. COVID-19 Vaccine Nonreplicating viral vector vaccines Example: Johnson & Johnson/Janssen, Oxford-AstraZeneca and Gam-COVID-Vac (Sputnik V) vaccines |
| DNA vaccines | The proposed mechanism is the insertion and expression of viral or bacterial DNA in human or animal cells (enhanced by the use of electroporation), triggering immune system recognition. | Under Trails (By Zydus Cadila) | COVID-19 |
National Immunization Schedule *
| For Infants | ||||
| BCG | At birth or as early as possible till one year of age | 0.1ml (0.05ml until 1 month of age) | Intra -dermal | Left Upper Arm |
| Hepatitis B Birth dose | At birth or as early as possible within 24 hours | 0.5 ml | Intramuscular | Anterolateral side of mid thigh-LEFT |
| OPV Birth dose | At birth or as early as possible within the first 15 days | 2 drops | Oral | – |
| OPV 1,2 & 3 | At 6 weeks, 10 weeks & 14 weeks | 2 drops | Oral | – |
| IPV (inactivated Polio Vaccine) | 14 weeks | 0.5 ml | Intramuscular | Anterolateral side of mid thigh-RIGHT |
| Pentavelant 1,2 & 3 | At 6 weeks, 10 weeks & 14 weeks | 0.5 ml | Intramuscular | Anterolateral side of mid thigh-LEFT |
| Rota Virus Vaccine | At 6 weeks, 10 weeks & 14 weeks | 5 drops | Oral | – |
| Measles 1st Dose | 9 completed months-12 months. (give up to 5 years if not received at 9-12 months age) | 0.5 ml | Subcutaneous | Right Upper Arm |
| Vitamin A, 1st Dose | At 9 months with measles | 1 ml (1 lakh IU) | Oral | – |
| For children | ||||
| DPT 1st booster | 16-24 months | 0.5 ml | Intramuscular | Anterolateral side of mid thigh-LEFT |
| OPV Booster | 16-24 months | 2 drops | Oral | |
| Measles 2nd dose | 16-24 Months | 0.5 ml | Subcutaneous | Right Upper Arm |
| Vitamin A (2nd to 9th dose) | 16 months with DPT/OPV booster, then, one dose every 6 month up to the age of 5 years) | 2 ml (2 lakh IU) | Oral | – |
| DPT 2nd Booster | 5-6 years | 0.5 ml. | Intramuscular | Left Upper Arm |
| TT | 10 years & 16 years | 0.5 ml | Intramuscular | Upper Arm |
*Source: National Health Mission in the State a separate Mission Directorate (NHM)
Some Vaccine under pipeline :
| Sr. No. | Name of Vaccine | Use | Company | Current Stage (till 2022) |
| 1 | Personalized cancer vaccine (PCV) | For Cancer | Merck | Development |
| 2 | KRAS vaccine | For Cancer | Merck | Development |
| 3 | Respiratory syncytial virus (RSV) vaccine | For Respiratory syncytial virus | Janssen Pharmaceutical Companies of Johnson & Johnson Pfizer | Phase 2/3 Development |
| 4 | Cytomegalo Virus Vaccine | To prevent cytomegalo virus (CMV) infection or curb virus re-activation | Moderna | Phase 2 |
| 5 | HIV Vaccine | To prevent HIV | Moderna | Clinical Trials |
| 6 | Zika vaccine | To prevent Zika virus | Moderna | Phase 2 |
| 7 | Nipah vaccine | To prevent Nipah virus | Moderna | Development |
| 8 | Myocardial ischemia (EPICCURE) | To demonstrate safety and tolerability in patients with heart failure | Astrazeneca | Phase 2 |
For Blood Pressure read :https://pharmasciences.in/explore/blood-pressure/
https://www.hhs.gov/immunization/basics/types/index.html
This website uses cookies.